Antonina Gendasz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonina Gendasz has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Obszańska
4th Military Clinical Hospital with Polyclinic SPZOZ in Wroclaw, Rudolfa Weigla 5, 50-981 Wroclaw
3 shared publications - Julia Tesyna
4th Military Clinical Hospital with Polyclinic SPZOZ in Wrocław, ul. Rudolfa Weigla 5, 50-981 Wrocław
3 shared publications - Kamil Marchlik
4th Military Hospital in Wroclaw
3 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 78, 76177
Congenital Nephrotic Syndrome: Etiology, Clinical Presentation, and a Comparison of Optimal Treatment Strategies – A Literature Review
Introduction: Congenital nephrotic syndrome is a rare condition with symptom onset occurring within the first three months of life. It affects approximately 1 to 3 per 100,000 live births. It has a varied etiology on a genetic, non-genetic, and infectious basis. While management primarily relies on symptomatic care, advances in modern medicine have significantly improved long-term outcomes, slowly ensuring affected children normal functioning in the future. Aim: The primary aim of this literature review is to synthesize current knowledge regarding the etiology and clinical presentation of CNS, and to compare the efficacy of evolving therapeutic methods, contrasting conservative medical management with radical surgical and renal replacement strategies. Keywords: Congenital Nephrotic Syndrome; NPHS1 Gene; Nephrin; Glomerular Filtration Barrier; Bilateral Nephrectomy; Kidney Transplantation; Pediatric Nephrology. Materials and methods: This study is a narrative literature review based on the analysis of scientific articles concerning congenital nephrotic syndrome (CNS). The reviewed studies included neonates and infants with CNS, focusing on genetic causes, medical and surgical management (nephrectomy), and kidney transplantation outcomes. Clinical guidelines, literature reviews, meta-analyse, cohort studies, and case reports published between 2001 and 2026 were analyzed. Conclusions: Congenital nephrotic syndrome (CNS) lacks a universal treatment protocol, demanding a strictly personalized, multidisciplinary approach tailored to the unique clinical, metabolic, and genetic profile of each infant. Early prenatal detection is critical for planned delivery in tertiary centers and immediate postnatal stabilization. While contemporary management remains purely symptomatic and supportive, optimizing long-term outcomes requires expanded multicenter registries and a decisive shift in research toward causal, gene- and molecular-targeted therapies.
- 21 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 78, 76177
Open AccessCongenital Nephrotic Syndrome: Etiology, Clinical Presentation, and a Comparison of Optimal Treatment Strategies – A Literature Review
Introduction: Congenital nephrotic syndrome is a rare condition with symptom onset occurring within the first three months of life. It affects approximately 1 to 3 per 100,000 live births. It has a varied etiology on a genetic, non-genetic, and infectious basis. While management primarily relies on symptomatic care, advances in modern medicine have significantly improved long-term outcomes, slowly ensuring affected children normal functioning in the future. Aim: The primary aim of this literature review is to synthesize current knowledge regarding the etiology and clinical presentation of CNS, and to compare the efficacy of evolving therapeutic methods, contrasting conservative medical management with radical surgical and renal replacement strategies. Keywords: Congenital Nephrotic Syndrome; NPHS1 Gene; Nephrin; Glomerular Filtration Barrier; Bilateral Nephrectomy; Kidney Transplantation; Pediatric Nephrology. Materials and methods: This study is a narrative literature review based on the analysis of scientific articles concerning congenital nephrotic syndrome (CNS). The reviewed studies included neonates and infants with CNS, focusing on genetic causes, medical and surgical management (nephrectomy), and kidney transplantation outcomes. Clinical guidelines, literature reviews, meta-analyse, cohort studies, and case reports published between 2001 and 2026 were analyzed. Conclusions: Congenital nephrotic syndrome (CNS) lacks a universal treatment protocol, demanding a strictly personalized, multidisciplinary approach tailored to the unique clinical, metabolic, and genetic profile of each infant. Early prenatal detection is critical for planned delivery in tertiary centers and immediate postnatal stabilization. While contemporary management remains purely symptomatic and supportive, optimizing long-term outcomes requires expanded multicenter registries and a decisive shift in research toward causal, gene- and molecular-targeted therapies.
- Open Access
- 11 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76176
The Effect of Resistance Training on Bone Mineral Density in the Lumbar Spine and Femoral Neck in Postmenopausal Women - literature review.
Introduction: Osteoporosis is a chronic disease of the skeletal system characterised by reduced bone strength and an increased risk of fractures. In postmenopausal women, estrogen deficiency accelerates bone loss. Resistance training provides mechanical stimuli that may help maintain or increase bone mineral density (BMD). Materials and methods: A narrative review of randomized controlled trials, intervention studies, systematic reviews, and meta-analyses was conducted. The analysis focused on changes in BMD measured by dual-energy X-ray absorptiometry (DXA), particularly at the lumbar spine and femoral neck, considering training intensity, frequency, duration, and progression. Aim of the study: To evaluate the effects of resistance training on BMD in postmenopausal women and assess the influence of training characteristics on its effectiveness. Conclusions: Resistance training may increase BMD or attenuate its decline in postmenopausal women. The most consistent effects were observed at the lumbar spine, while findings for the femoral neck were more heterogeneous. Higher intensity and progressive loading may provide a stronger osteogenic stimulus, although no single optimal protocol has been established. Further research is needed to determine optimal training parameters and their impact on fracture risk.
- 11 October 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 77, 76176
Open AccessThe Effect of Resistance Training on Bone Mineral Density in the Lumbar Spine and Femoral Neck in Postmenopausal Women - literature review.
Introduction: Osteoporosis is a chronic disease of the skeletal system characterised by reduced bone strength and an increased risk of fractures. In postmenopausal women, estrogen deficiency accelerates bone loss. Resistance training provides mechanical stimuli that may help maintain or increase bone mineral density (BMD). Materials and methods: A narrative review of randomized controlled trials, intervention studies, systematic reviews, and meta-analyses was conducted. The analysis focused on changes in BMD measured by dual-energy X-ray absorptiometry (DXA), particularly at the lumbar spine and femoral neck, considering training intensity, frequency, duration, and progression. Aim of the study: To evaluate the effects of resistance training on BMD in postmenopausal women and assess the influence of training characteristics on its effectiveness. Conclusions: Resistance training may increase BMD or attenuate its decline in postmenopausal women. The most consistent effects were observed at the lumbar spine, while findings for the femoral neck were more heterogeneous. Higher intensity and progressive loading may provide a stronger osteogenic stimulus, although no single optimal protocol has been established. Further research is needed to determine optimal training parameters and their impact on fracture risk.
- Open Access
- 21 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 74, 75968
Nitroxoline: A "Re-Emerging" Antibacterial Agent in the Prevention of Recurrent Urinary Tract Infection Based on Updated Worldwide Guidelines
Introduction. Urinary tract infections (UTIs) represent a critical global healthcare challenge, impacting over 404 million individuals annually. Escalating antimicrobial resistance among primary uropathogens, particularly to fluoroquinolones and broad-spectrum beta-lactams, has driven a critical paradigm shift toward antibiotic-sparing agents. Nitroxoline (5-nitro-8-hydroxyquinoline), an oral uroantiseptic, has re-emerged as a promising therapeutic alternative. Material and methods. This narrative review synthesizes current clinical and microbiological evidence regarding nitroxoline's mechanism of action, pharmacokinetics, safety profile, and resistance rates. Furthermore, it evaluates the drug's therapeutic positioning across updated international clinical guidelines published up to May 2026. Results. Nitroxoline exhibits broad-spectrum activity against Enterobacterales (including ESBL strains), urogenital mycoplasmas, and Candida species. Its antimicrobial effect is driven by the chelation of essential divalent metallic cations, which inhibits bacterial RNA polymerase, reduces biofilm synthesis, inhibits metallo-beta-lactamases, and impairs mucosal adhesion. Oral nitroxoline achieves rapid, high urinary concentrations with low disruption to native intestinal microflora. Clinical data demonstrate high tolerability (~96%) and a minimal discontinuation rate (~1.3%). Major European consensus guidelines (EAU, AWMF, SSGO) recommend nitroxoline as a first-line oral agent for acute localized cystitis and prophylaxis where available. Guidelines in non-registered regions omit the drug solely due to regional market unavailability. Conclusions. Nitroxoline is a potent, safe, and antibiotic-sparing uroantiseptic that aligns with global antimicrobial stewardship principles. Future efforts should focus on expanding clinical trials and clarifying its pharmacokinetics in renal impairment to fully utilize its therapeutic potential against resistant uropathogens.
- 21 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 74, 75968
Open AccessNitroxoline: A "Re-Emerging" Antibacterial Agent in the Prevention of Recurrent Urinary Tract Infection Based on Updated Worldwide Guidelines
Introduction. Urinary tract infections (UTIs) represent a critical global healthcare challenge, impacting over 404 million individuals annually. Escalating antimicrobial resistance among primary uropathogens, particularly to fluoroquinolones and broad-spectrum beta-lactams, has driven a critical paradigm shift toward antibiotic-sparing agents. Nitroxoline (5-nitro-8-hydroxyquinoline), an oral uroantiseptic, has re-emerged as a promising therapeutic alternative. Material and methods. This narrative review synthesizes current clinical and microbiological evidence regarding nitroxoline's mechanism of action, pharmacokinetics, safety profile, and resistance rates. Furthermore, it evaluates the drug's therapeutic positioning across updated international clinical guidelines published up to May 2026. Results. Nitroxoline exhibits broad-spectrum activity against Enterobacterales (including ESBL strains), urogenital mycoplasmas, and Candida species. Its antimicrobial effect is driven by the chelation of essential divalent metallic cations, which inhibits bacterial RNA polymerase, reduces biofilm synthesis, inhibits metallo-beta-lactamases, and impairs mucosal adhesion. Oral nitroxoline achieves rapid, high urinary concentrations with low disruption to native intestinal microflora. Clinical data demonstrate high tolerability (~96%) and a minimal discontinuation rate (~1.3%). Major European consensus guidelines (EAU, AWMF, SSGO) recommend nitroxoline as a first-line oral agent for acute localized cystitis and prophylaxis where available. Guidelines in non-registered regions omit the drug solely due to regional market unavailability. Conclusions. Nitroxoline is a potent, safe, and antibiotic-sparing uroantiseptic that aligns with global antimicrobial stewardship principles. Future efforts should focus on expanding clinical trials and clarifying its pharmacokinetics in renal impairment to fully utilize its therapeutic potential against resistant uropathogens.